cantharidin
Trade name: Ycanth
Approved
Jul 21, 2023
Cantharidin is a toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). Cantharidin is a medication used to remove warts and a viral skin infection called molluscum contagiosum. It is made from the secretions that come from the green blister beetle in combination with salicylic acid. It works by creating a blister just below the wart, which pushes the wart up and away from the underlying tissue, cutting of the blood supply to the wart. As the blister and the wart dry out, they both slough off, leaving fresh, unmarred skin behind. It is also used as an experimental anti-tumor agent. Several studies also show potential novel applications of cantharidin in acquired perforating dermatosis, acute herpes zoster, and leishmaniasis. In 1962, cantharidin lost Food and Drug Administration (FDA) approval owing to the failure of its manufacturers to submit data attesting to cantharidin's efficacy. However, in 1999, the FDA included cantharidin on its “Bulk Substances List” of drugs which although not available as commercial products, were approved for compounding on a customized basis for individual patients. — NCATS
Clinical trial activity
20 trials · 27 clinical orgs · 1 marketing orgs
Earliest trial started Jun 15, 2006 (NCT03625960)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2018
Verrica Pharmaceuticals Inc. — Earliest Phase 3 Sponsor(trial)
2020s
- Jul 21, 2023
Verrica Pharmaceuticals Inc. — Earliest FDA Approval
- Jul 21, 2023
Verrica Pharmaceuticals Inc. — Marketing Organization
- Jul 21, 2023
Verrica Pharmaceuticals Inc. — NDA Secondary Org
- Jul 21, 2023
Verrica Pharmaceuticals Inc. — NDA Organization
Indications
Approved for
Studied for
- Arthritis, Rheumatoid · Phase 1
- Blister · Early Phase 1
- Carcinoma, Verrucous · Phase 4
- Cardiovascular Diseases · Early Phase 1
- Condylomata Acuminata · Phase 4
- Dermatology · Phase 4
- DNA Virus Infections · Phase 2
- Inflammation · Phase 1
- Molluscum Contagiosum · Phase 3
- Papillomavirus Infections · Phase 2
- Sexually Transmitted Diseases · Phase 2
- Sexually Transmitted Diseases, Viral · Phase 2
- Skin Diseases · Phase 2
- Skin Diseases, Infectious · Phase 2
- Skin Diseases, Viral · Phase 2
- Tumor Virus Infections · Phase 2
- Virus Diseases · Phase 2
- Warts · Phase 3
Mechanism of action
- DNADEGRADER
DNA degrader
Approval history
- approvedJul 21, 2023
Chemistry & pharmacology
SMILES
C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O- Mol. weight
- 196.1999 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaCantharidin ↗
- NCATSIGL471WQ8P ↗
- ChEMBLCHEMBL48449 ↗
Also known as
- cantharidin
- cantharidin
- cantharidin
- vp-102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07246590 | Phase 3 | Dec 31, 2025 | Canfield Scientific Inc., Medidata Solutions, Verrica Pharmaceuticals Inc. |
| NCT07309419 | Phase 2/Phase 3 (Phase 3) | Dec 22, 2025 | Fudan University |
| NCT05597098 | Early Phase 1 (Phase 1) | Dec 1, 2022 | University of London |
| NCT05070754 | Phase 4 | Oct 1, 2021 | Columbia University, Medical University of South Carolina |
| NCT03981822 | Phase 2 | Jun 27, 2019 | BioClinica, Inc., Indiana Clinical Trials Center, Instat services, Paidion Research, Inc, Verrica Pharmaceuticals Inc. |
| NCT04308889 | Early Phase 1 (Phase 1) | Jul 2, 2018 | Harvard University, National Institute of General Medical Sciences (NIGMS) |
| NCT03487549 | Phase 2 | Mar 27, 2018 | BioClinica, Inc., Instat services, Paidion Research, Inc, Verrica Pharmaceuticals Inc., Wake Dermatology |
| NCT03377790 | Phase 3 | Mar 21, 2018 | Database Integrations, Instat services, Paidion Research, Inc, University of California, San Diego, Verrica Pharmaceuticals Inc. |
| NCT03426995 | Phase 1 | Mar 13, 2018 | GlaxoSmithKline |
| NCT03377803 | Phase 3 | Feb 14, 2018 | Database Integrations, Instat services, Paidion Research, Inc, University of California, San Diego, Verrica Pharmaceuticals Inc. |
| NCT03306589 | Phase 1 | Aug 11, 2017 | GlaxoSmithKline |
| NCT03186378 | Phase 2 | Jun 8, 2017 | Cato Research, Instat services, Paidion Research, Inc, Verrica Pharmaceuticals Inc. |
| NCT03017846 | Phase 2 | Sep 1, 2016 | Yeshiva University |
| NCT02665260 | Phase 2 | Jul 1, 2012 | Yeshiva University |
| NCT01582321 | Early Phase 1 (Phase 1) | Mar 1, 2012 | University of London |
| NCT01762787 | Phase 1 | Aug 17, 2010 | GlaxoSmithKline |
| NCT01026064 | Phase 1 | Jun 1, 2009 | GlaxoSmithKline |
| NCT00667225 | N/A | Jan 1, 2008 | Doris Duke Charitable Foundation, National Center for Research Resources (NCRR), University of North Carolina at Chapel Hill |
| NCT01084824 | N/A | Jun 1, 2007 | North Idaho Dermatology, Trident University |
| NCT03625960 | Phase 4 | Jun 15, 2006 | St. Vincents Hospital Manhattan, University of California, San Francisco, Wayne State University |
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. | For profit | 6 | 6 | 2 | 2017 |
| Instat services | For profit | 5 | 0 | 2 | 2017 |
| Paidion Research, Inc | For profit | 5 | 0 | 2 | 2017 |
| GlaxoSmithKline | For profit | 4 | 4 | 1 | 2009 |
| BioClinica, Inc. | For profit | 2 | 0 | 1 | 2018 |
| Database Integrations | For profit | 2 | 0 | 1 | 2018 |
| University of California, San Diego | Academic/Hospital | 2 | 0 | 1 | 2018 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Yeshiva University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Canfield Scientific Inc. | For profit | 1 | 0 | 1 | 2025 |
| Cato Research | For profit | 1 | 0 | 1 | 2017 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Doris Duke Charitable Foundation | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Indiana Clinical Trials Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Medical University of South Carolina | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Medidata Solutions | For profit | 1 | 0 | 1 | 2025 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2008 |
| National Institute of General Medical Sciences (NIGMS) | Government | 1 | 0 | 1 | 2018 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. | For profit | MKTG | Jul 21, 2023 |
| Verrica Pharmaceuticals Inc. | For profit | NDA2 | Jul 21, 2023 |
| Verrica Pharmaceuticals Inc. | For profit | NDA | Jul 21, 2023 |